Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell Jones

Showing results (421-430 of 463) with videos related to

Pageof 47
Sort By:
Diabetes|July 25, 2000
IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clampP V Carroll, E R Christ, A M Umpleby, et al.
Environmental Health : a Global Access Science Source|November 6, 2015
Projections of temperature-attributable premature deaths in 209 U.S. cities using a cluster-based Poisson approachJoel D Schwartz, Mihye Lee, Patrick L Kinney, et al.
The Journal of Clinical Endocrinology and Metabolism|August 12, 1999
The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patientsJ Gibney, J D Wallace, T Spinks, et al.
Lancet (London, England)|April 24, 2012
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialSimon Heller, John Buse, Miles Fisher, et al.
Diabetes Care|July 10, 2020
Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 DiabetesRoselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, et al.
Diabetes Care|February 20, 2021
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, et al.
Diabetes Care|March 21, 2022
The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 DiabetesRoselle A Herring, Fariba Shojaee-Moradie, Mary Stevenage, et al.
Metabolism: Clinical and Experimental|March 27, 2012
Fatty acid flux and oxidation are increased by rimonabant in obese womenKatharine Backhouse, Ivana Sarac, Fariba Shojaee-Moradie, et al.
European Journal of Clinical Investigation|June 1, 1995
A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteersD L Russell-Jones, A T Bates, A M Umpleby, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 29, 2013
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trialB W Bode, J B Buse, M Fisher, et al.
Pageof 47

Showing results (421-430 of 463) with videos related to

Sort By:
Pageof 47
Diabetes|July 25, 2000
IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clampP V Carroll, E R Christ, A M Umpleby, et al.
Environmental Health : a Global Access Science Source|November 6, 2015
Projections of temperature-attributable premature deaths in 209 U.S. cities using a cluster-based Poisson approachJoel D Schwartz, Mihye Lee, Patrick L Kinney, et al.
The Journal of Clinical Endocrinology and Metabolism|August 12, 1999
The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patientsJ Gibney, J D Wallace, T Spinks, et al.
Lancet (London, England)|April 24, 2012
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialSimon Heller, John Buse, Miles Fisher, et al.
Diabetes Care|July 10, 2020
Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 DiabetesRoselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, et al.
Diabetes Care|February 20, 2021
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, et al.
Diabetes Care|March 21, 2022
The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 DiabetesRoselle A Herring, Fariba Shojaee-Moradie, Mary Stevenage, et al.
Metabolism: Clinical and Experimental|March 27, 2012
Fatty acid flux and oxidation are increased by rimonabant in obese womenKatharine Backhouse, Ivana Sarac, Fariba Shojaee-Moradie, et al.
European Journal of Clinical Investigation|June 1, 1995
A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteersD L Russell-Jones, A T Bates, A M Umpleby, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 29, 2013
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trialB W Bode, J B Buse, M Fisher, et al.
Pageof 47